Document is current

Any future updates will be listed below

Correction to: Real-world efficacy and safety outcomes of acalabrutinib in chronic lymphocytic leukemia: primary results of a French multicentre observational study (NAOS)

Crossref DOI link: https://doi.org/10.1007/s00277-025-06632-3

Published Online: 2025-10-13

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark